<code id='A3F8FB45B4'></code><style id='A3F8FB45B4'></style>
    • <acronym id='A3F8FB45B4'></acronym>
      <center id='A3F8FB45B4'><center id='A3F8FB45B4'><tfoot id='A3F8FB45B4'></tfoot></center><abbr id='A3F8FB45B4'><dir id='A3F8FB45B4'><tfoot id='A3F8FB45B4'></tfoot><noframes id='A3F8FB45B4'>

    • <optgroup id='A3F8FB45B4'><strike id='A3F8FB45B4'><sup id='A3F8FB45B4'></sup></strike><code id='A3F8FB45B4'></code></optgroup>
        1. <b id='A3F8FB45B4'><label id='A3F8FB45B4'><select id='A3F8FB45B4'><dt id='A3F8FB45B4'><span id='A3F8FB45B4'></span></dt></select></label></b><u id='A3F8FB45B4'></u>
          <i id='A3F8FB45B4'><strike id='A3F8FB45B4'><tt id='A3F8FB45B4'><pre id='A3F8FB45B4'></pre></tt></strike></i>

          Home / explore / knowledge

          knowledge


          knowledge

          author:leisure time    Page View:21645
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In